Biogen News and Research

RSS
Research collaboration to tackle multiple sclerosis, motor neurone disease

Research collaboration to tackle multiple sclerosis, motor neurone disease

Biogen Idec announces acceptance of marketing applications for review of PLEGRIDY

Biogen Idec announces acceptance of marketing applications for review of PLEGRIDY

Biogen, Sobi present new data supporting clinical, safety profile of ELOCTATE for hemophilia A

Biogen, Sobi present new data supporting clinical, safety profile of ELOCTATE for hemophilia A

Biogen, Sobi present new findings from Phase 3 trial of ALPROLIX at XXIV ISTH Congress

Biogen, Sobi present new findings from Phase 3 trial of ALPROLIX at XXIV ISTH Congress

Pharma IQ releases new infographic summary of results from industry survey

Pharma IQ releases new infographic summary of results from industry survey

Biogen Idec seeks FDA BLA approval for PLEGRIDY to treat multiple sclerosis

Biogen Idec seeks FDA BLA approval for PLEGRIDY to treat multiple sclerosis

Biogen Idec announces FDA's acceptance of ELOCTATE BLA for treatment of hemophilia A

Biogen Idec announces FDA's acceptance of ELOCTATE BLA for treatment of hemophilia A

Neuroperspective reviews status and prospects of therapeutics for Parkinson's disease

Neuroperspective reviews status and prospects of therapeutics for Parkinson's disease

Isis Pharmaceuticals starts ISIS-SMNRx Phase 2 study in infants with SMA

Isis Pharmaceuticals starts ISIS-SMNRx Phase 2 study in infants with SMA

Keystone Symposia receives grant for Advanced Life Sciences Training Program

Keystone Symposia receives grant for Advanced Life Sciences Training Program

Biogen acquires TYSABRI stake from Elan

Biogen acquires TYSABRI stake from Elan

Biogen receives additional patent protection for MS drug TECFIDERA

Biogen receives additional patent protection for MS drug TECFIDERA

Early detection of PML may help improve survival and disability levels

Early detection of PML may help improve survival and disability levels

Biogen announces FDA acceptance of rFIXFc BLA for treatment of hemophilia B

Biogen announces FDA acceptance of rFIXFc BLA for treatment of hemophilia B

Biogen Idec, Sobi release data from rFVIIIFc and rFIXFc phase 3 trials on hemophilia

Biogen Idec, Sobi release data from rFVIIIFc and rFIXFc phase 3 trials on hemophilia

Elan agrees to restructure Tysabri collaboration with Biogen Idec

Elan agrees to restructure Tysabri collaboration with Biogen Idec

Positive top-line results from Biogen Idec’s peginterferon beta-1a Phase 3 trial on RRMS

Positive top-line results from Biogen Idec’s peginterferon beta-1a Phase 3 trial on RRMS

Elan, Biogen Idec submit applications to FDA and EMA for updation of TYSABRI labels

Elan, Biogen Idec submit applications to FDA and EMA for updation of TYSABRI labels

Scientists develop playbook to end devastating impact of fibrotic diseases

Scientists develop playbook to end devastating impact of fibrotic diseases